Compare FORTY & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | DMRA |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1998 | 2020 |
| Metric | FORTY | DMRA |
|---|---|---|
| Price | $117.08 | $20.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.89 |
| AVG Volume (30 Days) | 2.3K | ★ 519.7K |
| Earning Date | 11-19-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.68% | N/A |
| EPS Growth | N/A | ★ 121.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $102.01 | $16.50 |
| 52 Week High | $190.56 | $34.89 |
| Indicator | FORTY | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 40.58 |
| Support Level | $109.16 | $18.73 |
| Resistance Level | $119.68 | $26.76 |
| Average True Range (ATR) | 1.52 | 1.36 |
| MACD | -0.67 | 0.16 |
| Stochastic Oscillator | 28.17 | 50.46 |
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.